Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 93-100

  Jeong, Seri ^a   Park, Yongjung ^a   Cho, Yonggeun ^a   Kim, Young Ran ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bladder cancer; CYFRA 21 1; FDP; NMP22; UBC; Urinary tumor marker

Indexed keywords

CREATININE; CYTOKERATIN 19 FRAGMENT; FIBRIN DEGRADATION PRODUCT; NUCLEAR MATRIX PROTEIN 22; TUMOR ANTIGEN; UNCLASSIFIED DRUG; URINARY BLADDER CANCER ANTIGEN; ANTIGEN CYFRA21.1; CYTOKERATIN 19; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ELECTROCHEMILUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; IMMUNOTURBIDIMETRY; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS; BLADDER TUMOR; MIDDLE AGED; URINE;

AGED; ANTIGENS, NEOPLASM; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KERATIN-19; MALE; MIDDLE AGED; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84866290702     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.08.018     Document Type: Article

References (33)

1. Siegel, R., Ward, E., Brawley, O., Jemal, A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61 (2011), 212–236.
2. Messing, E.M., Young, T.B., Hunt, V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (1995), 387–396 discussion 96–7.
3. Shariat, S.F., Karam, J.A., Lotan, Y., Karakiewizc, P.I., Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10 (2008), 120–135.
4. Badalament, R.A., Hermansen, D.K., Kimmel, M., et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60 (1987), 1423–1427.
5. Mian, C., Lodde, M., Haitel, A., Vigl, E.E., Marberger, M., Pycha, A., Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55 (2000), 223–226.
6. Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T., Pode, D., Evaluation of urine CYFRA 21‐1 for the detection of primary and recurrent bladder carcinoma. Cancer 94 (2002), 2914–2922.
7. Sanchez-Carbayo, M., Urrutia, M., Silva, J.M., Romani, R., De Buitrago, J.M., Navajo, J.A., Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21‐1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 165 (2001), 1462–1467.
8. Schmetter, B.S., Habicht, K.K., Lamm, D.L., et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 158 (1997), 801–805.
9. Cancer AJCo, Urinary bladder. Fleming, I.D., (eds.) AJJC Cancer Staging Manual, 1997, Lippincott Williams & Wilkins, Baltimore, 241.
10. Mostofi, F.K., Sobin, L.H., Torloni, H., Histological typing of urinary bladder tumors (International Histologic Classification of Tumors, No. 10). 1973, World Health Organization, Geneva.
11. Black, P.C., Brown, G.A., Dinney, C.P., Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24 (2006), 5528–5535.
12. van Rhijn, B.W., van der Poel, H.G., van der Kwast, T.H., Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005), 736–748.
13. Sagnak, L., Ersoy, H., Gucuk, O., Ozok, U., Topaloglu, H., Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria. Urol Int 87 (2011), 35–41.
14. Sanchez-Carbayo, M., Herrero, E., Megias, J., Mira, A., Soria, F., Comparative sensitivity of urinary CYFRA 21‐1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 162 (1999), 1951–1956.
15. Kunze, E., Chang-Claude, J., Frentzel-Beyme, R., Life style and occupational risk factors for bladder cancer in Germany. A case–control study. Cancer 69 (1992), 1776–1790.
16. Sanchez-Carbayo, M., Espasa, A., Chinchilla, V., et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21‐1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45 (1999), 1944–1953.
17. Senga, Y., Kimura, G., Hattori, T., Yoshida, K., Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21‐1) in serum and urine of patients with bladder cancer. Urology 48 (1996), 703–710.
18. Lokeshwar, V.B., Habuchi, T., Grossman, H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 (2005), 35–63.
19. Ponsky, L.E., Sharma, S., Pandrangi, L., et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 166 (2001), 75–78.
20. Brown, F.M., Urine cytology. It is still the gold standard for screening?. Urol Clin North Am 27 (2000), 25–37.
21. Todenhofer, T., Hennenlotter, J., Kuhs, U., et al. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 79 (2012), 620–624.
22. Soloway, M.S., Briggman, V., Carpinito, G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156 (1996), 363–367.
23. Shariat, S.F., Casella, R., Khoddami, S.M., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171 (2004), 626–630.
24. Hong, Y.M., Loughlin, K.R., Economic impact of tumor markers in bladder cancer surveillance. Urology 71 (2008), 131–135.
25. Hungerhuber, E., Stepp, H., Kriegmair, M., et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007), 260–264.
26. Skacel, M., Fahmy, M., Brainard, J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003), 2101–2105.
27. Sumi, S., Arai, K., Kitahara, S., Yoshida, K.I., Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 296 (2000), 111–120.
28. Eissa, S., Swellam, M., Sadek, M., Mourad, M.S., El Ahmady, O., Khalifa, A., Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 168 (2002), 465–469.
29. Ramakumar, S., Bhuiyan, J., Besse, J.A., et al. Comparison of screening methods in the detection of bladder cancer. J Urol 161 (1999), 388–394.
30. Kosacka, M., Jankowska, R., Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21‐1 levels in non-small cell lung cancer. Pol Arch Med Wewn 119 (2009), 33–37.
31. Molina, R., Agusti, C., Mane, J.M., et al. CYFRA 21‐1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 9 (1994), 96–101.
32. Mungan, N.A., Vriesema, J.L., Thomas, C.M., Kiemeney, L.A., Witjes, J.A., Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 56 (2000), 787–792.
33. Shariat, S.F., Zippe, C., Ludecke, G., et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173 (2005), 1518–1525.